The Twenty Minute VCMark Goldberg: Why Politics is Rife & Decision-Making is Broken in Large VCs | E1219
CHAPTERS
- 0:00 – 2:21
Chemistry’s founding thesis: a “new” VC built for founder–investor alignment
Mark explains why the world doesn’t need another VC fund, but does need new fund designs that better align incentives with founders. He outlines Chemistry’s origin story: three experienced investors coming together to build a focused, ownership-minded early-stage firm.
- •“New fund” vs “another fund” framing
- •Designing incentives around founders’ needs (time, attention, direct relationships)
- •Small, focused team as a deliberate product choice
- •“Avengers” concept: experienced operators from big platforms joining forces
- 2:21 – 3:56
Why big firms drift out of alignment: portfolio creep, time scarcity, and bureaucracy
The conversation breaks down how time allocation becomes the core misalignment at large, mature platforms. Mark argues that as portfolios and organizations scale, senior investors spend less time on new deals and early founder support—precisely where it matters most.
- •Alignment is more about responsibilities and time than fund size alone
- •Portfolio “iceberg” effect: board seats and support load compound over time
- •Liquidity drought increases the carry/portfolio burden
- •Large-firm bureaucracy (management/admin) taxes partner attention
- 3:56 – 5:34
The “dirty secret” of platform services teams and why founders want direct investor access
Mark challenges the common claim that big platform teams (talent, BD, portfolio services) primarily benefit founders. He argues these functions often exist to help VCs scale something inherently unscalable, and can dilute the core founder–partner relationship.
- •Portfolio services can be designed to serve the VC organization more than founders
- •Division-of-labor enables scale, but can disintermediate the founder–partner bond
- •A16Z-era platform innovation: great intent, but can become a crutch
- •Founders often value direct access to an experienced check-writer
- 5:34 – 8:03
What “value-add” really means: do-no-harm vs early-stage ‘magic moments’
Harry argues many founders just want money and minimal interference; Mark agrees this is often true at later stages. But he pushes that early-stage value is about trust and availability during pivotal founder moments, not transactional recruiting intros.
- •Later-stage investor selection often reduces to price + staying out of the way
- •Early-stage: trust and founder support during high-stakes personal/company moments
- •“Magic moments” framework (late-night calls, cofounder issues, existential doubt)
- •Great investor can be “do no harm,” but excellent investor builds durable trust
- 8:03 – 10:34
Brand vs person: who chooses emerging firms and why legacy brands still matter
They debate when founders prioritize brand-name investors versus individual partners. Mark reframes it as “insider/outsider proximity” rather than age, and explains how Chemistry will win deals through network density and prior founder relationships.
- •Founder preference often correlates with ecosystem familiarity, not founder age
- •Legacy brands provide validation for outsiders entering Silicon Valley
- •New funds win through reputational networks and alumni/portfolio spinouts
- •Chemistry’s name reflects the importance of tight partner–founder dynamics
- 10:34 – 12:27
Venture’s industrialization: from boutique craft to commoditized scale—and the boutique reversal bet
Reacting to Doug Leone’s quote, Mark argues venture has industrialized: bigger AUM, larger teams, and less clarity on who actually writes checks. Chemistry positions itself as a contrarian return to boutique models inspired by Benchmark and USV.
- •Industrialization = brand recognition without partner-level familiarity
- •Team-size/AUM expansion changes how founders experience firms
- •Boutique early-stage relationships as a competitive advantage
- •Contrarian strategy: smaller, focused partnership-led investing
- 12:27 – 15:18
Portfolio construction: why a $350M seed/A fund, what ‘Series A’ means now, and reserves philosophy
Mark details Chemistry’s $350M size and bottoms-up pacing assumptions (2–3 deals per GP per year). He explains how “Series A” has stretched in dollar terms, and why Chemistry uses a light-reserve approach instead of pro-rata ‘peanut buttering.’
- •Fund size derived from target pace and number of investments (~25)
- •Series A inflation: $15M rounds becoming $30–40M (even excluding mega-AI)
- •Chemistry targeting earlier “click in front” As with $10–15M leads
- •Light reserves model; selective doubling down vs broad pro-rata participation
- 15:18 – 17:50
Competing in today’s market: seed round inflation, paying up for category winners, and founder conviction
They discuss the reality of larger seed rounds and when it’s rational to pay up. Mark emphasizes stretching on price when conviction is extreme and the company can be the category winner, with founder quality as a major deciding variable.
- •“Play the game on the field”: good companies still emerge in any vintage
- •Avoiding deals that break risk/return even if they’re fashionable
- •Pay up when it’s likely the category winner (avoid #2/#3 outcomes)
- •Founder/team conviction as the tie-breaker for price flexibility
- 17:50 – 21:00
Competitive markets and execution failure: resilience pre-PMF and hiring quality post-PMF
Mark explains why competitive markets don’t deter him if a founder can out-execute. He then separates common execution failure modes: pre-PMF success depends on grit and learning velocity, while post-PMF failure often comes from leadership hiring mistakes—especially in go-to-market.
- •Competitive markets can validate opportunity; execution is the differentiator
- •Pre-PMF: resilience and learning velocity matter more than OKR hygiene
- •Post-PMF: leadership hiring and function heads become the bottleneck
- •Transition from founder-led sales to professional GTM is a critical inflection
- 21:00 – 23:45
First-time vs serial founders—and why Chemistry isn’t for founders seeking legacy validation
Forced to choose, Mark prefers first-time founders for their clean-slate ambition and hunger, with nuanced caveats about “chip on shoulder” profiles. He also states plainly that Chemistry is not the right fit for founders who primarily want a decades-old brand name.
- •First-time founder upside: naivety + ambition can be transformative
- •Best repeat profile: tried before, didn’t break through, returns hungry
- •Financially “comfortable” repeat founders may lack the same edge
- •Legacy brand mainly helps with future funding—less so with hiring/customers
- 23:45 – 29:37
Raising Chemistry’s fund: LP zeitgeist, meeting strategy, and what ‘good LP behavior’ looks like
Mark walks through raising in the summer (June–August), tapping LP frustration with VC firms turning into asset managers. He shares mechanics (in-person meetings, heavy travel, pre-screening) and reflects on how fundraising builds empathy and reveals what high-quality LP communication looks like.
- •LP appetite for ‘pure play venture’ + hustle during a cycle shift
- •Fundraise timing and speed; kept largest LPs under ~10% and targeted ~20 LPs
- •Pre-screening for first-fund appetite to avoid low-probability meetings
- •Fundraising empathy: pitching pressure and the value of direct feedback
- 29:37 – 36:41
No’s, best/worst LP meetings, and partnership building: junior team debate and in-office culture
They cover the most common rejection reason—team risk from three partners who hadn’t worked together—and how Mark pushed for more honest feedback. Mark shares memorable LP meeting stories, then pivots to internal partnership decisions: building a small junior team and committing to in-office work.
- •Top ‘no’: perceived team risk and new-fund structure
- •Best LP traits: clarity, speed to conviction, direct communication
- •Worst meetings: being asked to justify venture as an asset class
- •Internal disagreement: GP-only vs small junior team; decision to hire two juniors; in-office every day
- 36:41 – 44:22
Cycle realities: extended privatization, 2021 vintage pain, inflated valuations—and AI deal mania vs decision discipline
Mark argues the market will innovate toward more liquidity options even if companies stay private longer, but notes LPs often model 15-year fund durations. They discuss 2021 vintage challenges and how overinflated private marks hurt morale, then turn to AI froth and Chemistry’s single-trigger decision model designed to avoid consensus mediocrity.
- •Liquidity duration vs company privatization; expectation of more secondaries/products
- •2021 vintage headwinds and why those funds may underperform
- •Overpriced late-stage marks damage internal morale and execution
- •AI bubble dynamics: ‘.AI premium’ fading in some areas, but mega-round craziness persists
- •Single-trigger investing to prevent consensus-driven omission errors; accepting more variance
- 44:22 – 51:02
Founder-over-market bias, category allergies, and saying ‘no’ better (plus fund mechanics: check size vs ownership)
Mark explains he’ll back an amazing founder even in an unattractive market, arguing great founders can create or expand TAM. He cautions against experience-driven category blind spots, discusses becoming more candid in rejections after fundraising, and closes with portfolio mechanics: he’ll bend on check size before ownership and avoids >10% fund concentration in one company.
- •Back great founders even in “bad markets,” including uncomfortable categories like lending
- •Experience can create dangerous mental shortcuts; don’t shut off categories entirely
- •Turning founders down: constructive honesty beats polite vagueness; optionality differs by fund type
- •Compromise: increase check size before giving up ownership; concentration comfort around <10% per company
- 51:02 – 56:17
Quick-fire: mentors, groupthink, operating with a clean slate, and what makes investors truly great
In rapid questions, Mark cites Mike Volpe as his biggest learning source and calls out venture groupthink as harmful. He describes the ‘jetpack’ energy of starting fresh versus carrying legacy portfolio load, and ends on a reflective question about whether wealth makes investors better—arguing love of the craft matters more than money.
- •Key mentor: Mike Volpe; ongoing advice loop
- •What he’d change in venture: reduce groupthink and gossip dynamics
- •Clean-slate advantage: early ‘offense’ mode feels uniquely powerful
- •Fund picks and thoughts on constrained growth strategies
- •Wealth vs performance: craft obsession and intensity drive great investors more than fearlessness
